Olodaterol, a long-acting beta₂-adrenergic agonist (LABA), was developed in the early 2000s and approved for medical use in the mid-2010s. It is primarily used as a maintenance bronchodilator therapy for chronic obstructive pulmonary disease (COPD). Olodaterol works by selectively stimulating beta₂ receptors in the smooth muscle of the airways, leading to relaxation of bronchial muscles, improved airflow, and long-lasting bronchodilation.
Olodaterol is typically used as an inhaled medication and is often combined with other bronchodilators, such as anticholinergic agents, to improve respiratory function in COPD patients. It is valued for its once-daily dosing and sustained duration of action, which helps improve lung function and reduce symptoms like shortness of breath. It is not used for acute bronchospasm relief but rather for long-term maintenance therapy.
BRAND NAMES
Striverdi Respimat – the main brand name used for maintenance treatment of chronic obstructive pulmonary disease (COPD)
Stiolto Respimat – combination inhaler containing olodaterol with tiotropium for improved bronchodilation in COPD.
MECHANISM OF ACTION
Olodaterol is a long-acting beta₂-adrenergic agonist (LABA) that selectively stimulates beta₂ receptors in the smooth muscle of the airways. This activation increases cyclic adenosine monophosphate (cAMP) levels, leading to relaxation of bronchial smooth muscle, bronchodilation, and improved airflow. It provides prolonged airway dilation and is used for maintenance therapy in chronic obstructive pulmonary disease (COPD), not for acute symptom relief.
PHARMACOKINETICS
Absorption:
Olodaterol is administered by inhalation and is rapidly absorbed through the lungs, producing local bronchodilation with minimal systemic exposure.
Distribution:
It is distributed primarily in the lungs with low systemic distribution. Plasma protein binding is moderate.
Metabolism:
Olodaterol is metabolized in the liver mainly through glucuronidation and, to a lesser extent, by cytochrome P450 pathways.
Elimination:
It is excreted mainly in urine (as metabolites) and to a lesser extent in feces. It has a long duration of action supporting once-daily dosing.
PHARMACODYNAMICS
Olodaterol produces bronchodilation by selectively stimulating beta₂-adrenergic receptors in airway smooth muscle. This reduces bronchoconstriction, improves lung function, and helps relieve chronic respiratory symptoms such as dyspnea. Its prolonged receptor activity allows sustained 24-hour bronchodilation.
ADMINISTRATION
Olodaterol is administered via inhalation using a soft mist inhaler device. It is used once daily at the same time each day for long-term maintenance treatment of COPD. It is not intended for sudden breathing attacks or acute bronchospasm.
DOSAGE AND STRENGTH
Olodaterol is commonly available as an inhalation solution delivering 2.5 mcg per actuation. The usual adult dose is two inhalations once daily, providing a total daily dose of 5 mcg.
DRUG INTERACTIONS
Olodaterol may have additive effects when used with other sympathomimetic agents, increasing the risk of cardiovascular side effects such as tachycardia. Caution is required when combined with beta-blockers, as they may reduce its bronchodilatory effect.
FOOD INTERACTIONS
Olodaterol has no significant food interactions since it is administered by inhalation.
CONTRAINDICATIONS
Olodaterol is contraindicated in patients with known hypersensitivity to the drug or any component of its formulation. It should not be used as a rescue therapy for acute bronchospasm.
SIDE EFFECTS
Common side effects include:
Cough
Nasopharyngitis
Dizziness
Headache
Tremor
Palpitations
OVER DOSAGE
Overdose of olodaterol, a long-acting beta₂-agonist used in COPD maintenance therapy, may lead to exaggerated pharmacologic effects. Symptoms can include tachycardia, palpitations, tremor, nervousness, headache, dizziness, hypertension or hypotension, and muscle cramps.
TOXICITY
Olodaterol overdose may lead to exaggerated beta-agonist effects such as tachycardia, hypertension or hypotension, tremors, nervousness, and hypokalemia. Severe cases may involve cardiac arrhythmias. Treatment is supportive, including monitoring of cardiovascular status and correction of electrolyte imbalances.
